Avalo Therapeutics, Inc. (AVTX) Stock Price & Analysis
Avalo Therapeutics, Inc. (AVTX) rose 3.83% to USD 18.44 as of July 25, 2026 at 11:15 UTC, according to Nexqual real-time market data.
AVTX last closed at USD 17.76; the session ranged USD 17.55–18.53 on volume of 783,841 shares. Market capitalization is $975.53M, with a 52-week range of USD 6.21–24.27 (NCM). Source: Nexqual, July 25, 2026 at 11:15 UTC.
Key Statistics (as of July 25, 2026 at 11:15 UTC)
| Price | USD 18.44 |
|---|---|
| Change | ▲ 3.83% (up) |
| Previous Close | USD 17.76 |
| Open | USD 18.01 |
| Day Range | USD 17.55 – 18.53 |
| 52-Week Range | USD 6.21 – 24.27 |
| Volume | 783,841 shares |
| Market Cap | $975.53M |
| Exchange | NCM |
Technical Analysis (AVTX)
Nexqual's technical model rates AVTX "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 11:15 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.92 (neutral) |
| vs SMA50 | Above (USD 16.88) |
| MACD | 0.42 (positive) |
Analyst Ratings (AVTX)
Wall Street analysts rate AVTX "Strong Buy" based on 13 analysts, with a mean price target of USD 44.69 (range USD 34–60), per Nexqual as of July 25, 2026 at 11:15 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 44.69 |
| High Target | USD 60 |
| Low Target | USD 34 |
| Buy / Hold / Sell | 15 / 0 / 0 |
Earnings (AVTX)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.62 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.98 vs est -1.07 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -1.5 ▲ beat |
| 2025-09-30 | USD -2.19 vs est -1.64 ▼ miss |
| 2025-06-30 | USD -1.92 vs est -1.46 ▼ miss |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Financials & Fundamentals (AVTX)
| Total Revenue | $59,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -134164.40% |
| Profit Margin | +0.00% |
| ROE | -88.76% |
| Debt / Equity | 0.48 |
| Current Ratio | 7.66 |
| Total Cash | $81.99M |
| Total Debt | $328,000 |
| Free Cash Flow | $-23.25M |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Financial Health Score (AVTX)
Nexqual rates Avalo Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 11:15 UTC.
| Growth | Critical — Revenue -87% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $82M cash, no debt |
| Cash Flow | Weak — FCF negative: -$23M, burning cash |
| Efficiency | Critical — ROE -89%, ROA -41.5% |
Ownership (AVTX)
| Insider Ownership | +1.73% |
|---|---|
| Institutional Ownership | +77.04% |
| Shares Outstanding | 52.90M |
| Float | 40.39M |
| Short % of Float | +24.01% |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Leadership (AVTX)
Avalo Therapeutics, Inc. is led by Garry A. Neil (age 71), President, CEO & Director, per Nexqual as of July 25, 2026 at 11:15 UTC.
| President, CEO & Director | Garry A. Neil (age 71) |
|---|---|
| Founder and Chairman of Scientific Advisory Board | Solomon H. Snyder (age 86) |
| CFO & Head of Investor relations | Christopher Ryan Sullivan (age 41) |
| Senior Vice President of Human Resources | Ashley Ivanowicz |
| Senior Vice President of CMC & Technical Operations | Dino C. Miano |
Major Backers & Investors (AVTX)
Notable institutional backers of Avalo Therapeutics, Inc. include T. Rowe Price, FMR, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 11:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 6.62% |
| FMR, LLC | 5.44% |
| Fidelity | 3.43% |
| Caligan Partners, LP | 3.09% |
| BVF Inc. | 3.09% |
| Avoro Capital Advisors LLC | 2.67% |
| Affinity Asset Advisors, Llc | 2.53% |
| Nantahala Capital Management, LLC | 2.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 3.82% |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
From Avalo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- United States Government Regulation In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the Public Health Service Act, and its implementing regulations.
- State and foreign laws, including for example the European Union General Data Protection Regulation, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
- Intellectual Property Overview Our success depends in part on our ability to obtain and maintain proprietary protection for the technology and know-how upon which our product candidates are based, to operate without infringing the proprietary rights of third parties and to prevent third parties from infringing our proprietary rights.
- We also rely on trade secrets and proprietary know-how, including manufacturing and formulation know-how, as well as confidentiality agreements and other contractual protections, to protect aspects of our technology and product candidates that may not be patentable or that we elect not to patent.
Partnerships
- We are responsible for the development and commercialization of the program. 2 Table of Contents We are required to pay Lilly up to $70 million based on the achievement of specified development and regulatory milestones.
- Upon commercialization, we are required to pay sales-based milestones aggregating up to $650 million payable to Lilly and up to $70 million to Leap.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TPST | Tempest Therapeutics, Inc. | USD 0.93 | ▼ 2.64% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.12 | ▼ 1.69% |
| ICU | SeaStar Medical Holding Corpora | USD 3.75 | ▼ 3.6% |
| NVOS | Novo Integrated Sciences, Inc. | USD 0 | ▲ 0% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:15 UTC. This page is informational and not investment advice.